Therapeutic Results in Patients with Hodgkin's Lymphoma Treated with Brentuximab Vedotin — Bulgarian Experience

Abstract Background: The introduction of Brentuximab Vedotin (BV) into clinical practice has improved the prognosis and survival of patients with Hodgkin's lymphoma, relapsed after stem cell transplantation or primary refractory disease. Aim: In patients with Hodgkin's lymphoma treated with Brentuximab Vedotin (BV), the overall response rate (ORR), type of response, event free survival (EFS) and the prognostic factors affecting them are analyzed. Patients and methods: Fourty-four (44) Hodgkin lymphoma patients treated with BV in 5 hematology clinics in Bulgaria were studied. The male / female ratio is 1.1 / 1, the mean age is 39.98 +/- 12.48. The most common histological variant is nodular sclerosis 31 (70.5%). In the II clinical stage there were 13 patients (29.5%), III - 16 (36.4%), IV -15 (34.1%). B-symptoms had 36 patients (81.8%), extranodal involvement - 17 (15.9%) and large mediastinal tumor mass - 14 (31.8%). All patients before treatment with BV received 4 (2-12) treatment lines, 50.0% -3 lines, 27.3% - 4 lines, and 9.1% > / = 5 lines. Stem cell transplantation was performed in 33 patients (75.0%), two of which were two autologous STCs, and in one auto/ allo SCT. Results: ORR is 60.0% (N=24) - complete response was achieved in 10 (25.0%) and partial in 14 (35.0%) patients. Stable disease was registered in 7 (17.5%) and progression in 9 (20,5%). Patients achieving at least a partial therapeutic response prior to commencement of BV treatment significantly improved their response at the end of treatment: 15 (62.5%) versus 9 (37.5%) with previous progression and stable disease (P Disclosures Goranova Marinova: Amgen: Consultancy, Honoraria; Roche: Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; Baxalta/Shire: Honoraria, Research Funding.